ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CPT Concepta Plc

1.98
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Concepta Plc LSE:CPT London Ordinary Share GB00BYZ2R301 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.98 1.90 2.20 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Concepta PLC Board Changes (1891T)

13/11/2019 7:01am

UK Regulatory


Concepta (LSE:CPT)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Concepta Charts.

TIDMCPT

RNS Number : 1891T

Concepta PLC

13 November 2019

Concepta PLC

("Concepta" or the "Company")

Board Changes

Concepta PLC (AIM: CPT), the innovative UK personalised healthcare company and developer of the proprietary self-test platform ("myLotus(R)") the most accurate home-use fertility tracking and pregnancy testing system available on the U.K. market, announces that Matthew Walls, Chairman will step down with immediate effect, by mutual agreement.

Non-Executive Director Adam Reynolds will take on the role as Non-Executive Chairman with immediate effect. The Company has identified, and is in the final stages of appointing a highly experienced Chief Executive and additional Non-Executive Director, each with a distinguished track record in women's fertility and healthcare.

A further announcement will be made shortly once the Company's NOMAD has completed all regulatory due diligence required for their appointments.

Adam Reynolds commented: "I would like to thank Matthew for his efforts over the past 18 months, during this period the Company has achieved a number of key milestones including the first birth from the myLotus product.

The Company is poised to announce a number of further births in the coming months and the new management team which will be announced shortly will take us through the next phase of growth."

Enquiries:

 
 Concepta plc                                    www.conceptaplc.com 
 Adam Reynolds, Non-Executive Chairman      Mob: +44 (0)7785 908 158 
 
 SPARK Advisory Partners Limited             Tel: +44 (0)20 368 3550 
  (NOMAD) 
 Neil Baldwin / Mark Brady 
 
 Novum Securities (Broker)                  Tel: +44 (0)20 7399 9400 
 Colin Rowbury 
 
 Walbrook PR Ltd (Media & Investor          Tel: +44 (0)20 7933 8780 
  Relations) 
 Paul McManus                            lifesciences@walbrookpr.com 
 

About Concepta PLC (www.conceptaplc.com)

Concepta PLC is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus(R), targeted at the personalized mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.

myLotus(R) is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus(R) is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.

The Company has received CE-mark certification for myLotus(R) and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2019.

myLotus(R) is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOADBBDBRBBBGCD

(END) Dow Jones Newswires

November 13, 2019 02:01 ET (07:01 GMT)

1 Year Concepta Chart

1 Year Concepta Chart

1 Month Concepta Chart

1 Month Concepta Chart

Your Recent History

Delayed Upgrade Clock